Can mavacamten cure cardiac hypertrophy?

Mavacamten (mavacamten) is a new treatment drug for hypertrophic cardiomyopathy (HCM). Although it shows good promise in improving patients' cardiac function and quality of life, it cannot yet be claimed to be able to cure HCM. Hypertrophic cardiomyopathy is a complex disease caused by abnormal thickening of myocardial tissue and its main features include left ventricular hypertrophy, hypersystole, and diastolic dysfunction. The disease often causes a series of symptoms, such as dyspnea, fatigue, chest pain and syncope, which seriously affects the patient's daily life and functional status.

As a small molecule drug, Mavakatai selectively acts on cardiac myosin, which can effectively inhibit excessive contraction of the myocardium and reduce the burden on the heart, thereby improving the patient's symptoms and cardiac function. In the Explorer-HCM trial, 251 patients were randomly divided into two groups to receive Mavacartide or placebo. The results showed that patients receiving Mavacartid showed significant improvements in multiple cardiac parameters and cardiopulmonary health. Studies have shown that this treatment regimen not only relieves symptoms in HCM patients, but also optimizes the physiological function of the heart.

Subsequent pre-specified analyzes of theobstructive-HCM trial further explored the effect of Mavacate on cardiopulmonary exercise testing (CPET) parameters. Research results show that the Mavakatai group has improved in multiple indicators such as peak VE/VCO2 ratio, metabolic equivalents, and circulation kinetics during exercise. These improvements provide a new perspective on understanding the clinical effects of mavacate, suggesting that the drug may improve patients' exercise capacity and endurance by improving diastolic function, allowing the heart more time to fill.

It is worth noting that although Mavacartide has shown positive efficacy in clinical trials, it cannot completely cure HCMHCM. The pathological mechanism of HCM is complex and involves genetic factors, structural abnormalities and corresponding physiological adaptations. Therefore, although Mavaceta can effectively improve symptoms and cardiac function, it still cannot eliminate the underlying cause of HCM. In addition, most HCM patients are unable to engage in high-intensity exercise due to limited cardiac function, so parameters based on non-maximum exercise testing may have more reference value when evaluating their long-term effects.

The use of Mavakatai also reminds us that The management of HCM needs to comprehensively consider many factors, including the patient's overall health status, underlying diseases and psychological state. Therefore, when doctors formulate individualized treatment plans, they should not only consider drug treatment, but also combine lifestyle adjustments, regular monitoring, and necessary cardiac rehabilitation training to ensure that patients get the best treatment results.

Reference materials:https://www.escardio.org/Sub-specialty-communities/European-Association-of-Preventive-Cardiology-(EAPC)/News/mavacamten-helping-patients-with-hcm-to-become-active-again